Proximity to Discovery: Scaling Up Industry Engagement Capability at the University of Bristol
Lead Research Organisation:
University of Bristol
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills. The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities. This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes. Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.
Organisations
- University of Bristol (Lead Research Organisation)
- Biogen (Collaboration)
- EVOTEC (Collaboration)
- Oracle Corporation (Collaboration)
- Pfizer Ltd (Collaboration)
- Bristol-Myers Squibb (Collaboration)
- Takeda Pharmaceutical Company (Collaboration)
- Medicines Discovery Catapult (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
People |
ORCID iD |
| Description | Flexible Talent Mobility Award |
| Amount | £16,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2018 |
| End | 03/2019 |
| Description | Innovate UK KTP with UCB (Moin Saleem) |
| Amount | £150,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 03/2021 |
| Description | Biogen Identifying the causal role of gene/protein expression on human diseases |
| Organisation | Biogen |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Expertise on Identifying the causal role of gene/protein expression on human diseases |
| Collaborator Contribution | Application of expertise to drug development pipeline |
| Impact | 1. in-house MR study on Biogen's drug target portfolio conducted and published 2. Sharing of datasets between Biogen and Bristol University 3. Conference talk given at the Mendelian Randomisation Conference 2019 4. Biogen to fund a three year post-doctoral post £300K 5. Conference paper accepted at ASHG conference 2020 |
| Start Year | 2018 |
| Description | Evotech and Bristol Renal |
| Organisation | Evotec |
| Country | Germany |
| Sector | Private |
| PI Contribution | Kidney cell lines |
| Collaborator Contribution | Funding for next phase of research |
| Impact | £400k direct investment |
| Start Year | 2018 |
| Description | External Advisory Board for MR Base |
| Organisation | Biogen |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Development of platform for using genetic data to predict the outcomes of clinical trials |
| Collaborator Contribution | Membership of external advisory board |
| Impact | External Advisory Board |
| Start Year | 2018 |
| Description | External Advisory Board for MR Base |
| Organisation | Bristol-Myers Squibb |
| Department | Celgene |
| Country | United States |
| Sector | Private |
| PI Contribution | Development of platform for using genetic data to predict the outcomes of clinical trials |
| Collaborator Contribution | Membership of external advisory board |
| Impact | External Advisory Board |
| Start Year | 2018 |
| Description | External Advisory Board for MR Base |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Development of platform for using genetic data to predict the outcomes of clinical trials |
| Collaborator Contribution | Membership of external advisory board |
| Impact | External Advisory Board |
| Start Year | 2018 |
| Description | External Advisory Board for MR Base |
| Organisation | Takeda Pharmaceutical Company |
| Country | Japan |
| Sector | Private |
| PI Contribution | Development of platform for using genetic data to predict the outcomes of clinical trials |
| Collaborator Contribution | Membership of external advisory board |
| Impact | External Advisory Board |
| Start Year | 2018 |
| Description | GSK Vaccines Neisserial vaccine development and evaluation |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Neisserial vaccine development and evaluation |
| Collaborator Contribution | Application of research to vaccine development pipeline |
| Impact | GSK to fund PhD student for 3 years £150K. Disciplines include cellular and molecular medicine and population health. |
| Start Year | 2018 |
| Description | GSK collaboration on Application of Mendelian randomization to predict therapeutic effect |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Provided platform for using genetic data to predict the outcome of clinical trials |
| Collaborator Contribution | Applied to above platform to pipeline of clinical trials |
| Impact | Direct funding for post-doc |
| Start Year | 2018 |
| Description | Medicines Discovery Catapult work on Modified Cytisiniclines as Novel and Selective Smoking Cessation Agents |
| Organisation | Medicines Discovery Catapult |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Modified Cytisiniclines as Novel and Selective Smoking Cessation Agents |
| Collaborator Contribution | Acted as CRO |
| Impact | Ongoing |
| Start Year | 2019 |
| Description | Oracle cloud computing collaborations |
| Organisation | Oracle Corporation |
| Department | Oracle Corporation UK Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Providing worked examples of biomedical research projects which would benefit from cloud computing |
| Collaborator Contribution | Free cloud computing credits |
| Impact | Collaboration across chemistry, population health and synthetic biology. Main impact is increasing computing speed dramatically. |
| Start Year | 2018 |
| Description | Pfizer collaboration around paediatric vaccinations |
| Organisation | Pfizer Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Expertise in paediatric vaccines and access to local health and social care system |
| Collaborator Contribution | Funding of centre for excellence |
| Impact | Centre for Excellence funded. |
| Start Year | 2018 |